Elite Pharmaceuticals (ELTP)
(Delayed Data from OTC)
$0.20 USD
+0.01 (2.83%)
Updated Aug 23, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
ELTP 0.20 +0.01(2.83%)
Will ELTP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ELTP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ELTP
Elite Pharmaceuticals (ELTP) Posts Breakeven Q1 Earnings
The Zacks Analyst Blog Highlights Danaher, Morgan Stanley, Pfizer, Elite Pharmaceuticals and Oil-Dri
ELTP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Initiates Coverage of Elite Pharmaceuticals With Outperform Recommendation
Elite Pharmaceuticals' (ELTP) FY24 Earnings Up, Gross Margin Down
Other News for ELTP
Elite Pharmaceuticals, Inc. (ELTP) Q1 2025 Earnings Call Transcript
Elite Pharmaceuticals reports Q1 results
ELTP Stock Earnings: Elite Pharmaceuticals Reported Results for Q1 2025
Elite Pharmaceuticals: Navigating Stock Market Complexities
Elite Pharmaceuticals Inc (ELTP) Reports Q1 FY2025 Revenue of $18. ...